Kobayashi Pharmaceutical Dividends and Buybacks
Dividend criteria checks 3/6
Kobayashi Pharmaceutical is a dividend paying company with a current yield of 1.59% that is well covered by earnings. Next payment date is on 7th March, 2025 with an ex-dividend date of 27th December, 2024.
Key information
1.6%
Dividend yield
2.5%
Buyback Yield
| Total Shareholder Yield | 4.1% |
| Future Dividend Yield | 1.7% |
| Dividend Growth | 2.2% |
| Next dividend pay date | 07 Mar 25 |
| Ex dividend date | 27 Dec 24 |
| Dividend per share | JP¥101.000 |
| Payout ratio | 74% |
Recent dividend and buyback updates
Recent updates
Earnings Tell The Story For Kobayashi Pharmaceutical Co., Ltd. (TSE:4967)
Dec 26
Calculating The Intrinsic Value Of Kobayashi Pharmaceutical Co., Ltd. (TSE:4967)
Nov 27Kobayashi Pharmaceutical's (TSE:4967) Soft Earnings Are Actually Better Than They Appear
Aug 21Getting In Cheap On Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) Is Unlikely
Aug 04Investor Optimism Abounds Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) But Growth Is Lacking
Apr 21Estimating The Fair Value Of Kobayashi Pharmaceutical Co., Ltd. (TSE:4967)
Apr 03Investors Met With Slowing Returns on Capital At Kobayashi Pharmaceutical (TSE:4967)
Feb 27Stability and Growth of Payments
Fetching dividends data
Stable Dividend: 4967's dividends per share have been stable in the past 10 years.
Growing Dividend: 4967's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| Kobayashi Pharmaceutical Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (4967) | 1.6% |
| Market Bottom 25% (JP) | 1.8% |
| Market Top 25% (JP) | 3.8% |
| Industry Average (Personal Products) | 2.2% |
| Analyst forecast (4967) (up to 3 years) | 1.7% |
Notable Dividend: 4967's dividend (1.59%) isn’t notable compared to the bottom 25% of dividend payers in the JP market (1.83%).
High Dividend: 4967's dividend (1.59%) is low compared to the top 25% of dividend payers in the JP market (3.8%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (73.9%), 4967's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: 4967 is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 19:59 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kobayashi Pharmaceutical Co., Ltd. is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mitsuko Miyasako | Barclays |
| Ritsuko Tsunoda | BofA Global Research |
| Daisuke Yamaguchi | Citigroup Global Markets Japan Inc. |